
Management ChangeOct 13, 2026, 08:41 AM
MetaVia Appoints Sarah Browne, M.D. as Chief Medical Officer
AI Summary
MetaVia Inc. announced the appointment of Sarah Kaplan Browne, M.D. as its new Chief Medical Officer, effective October 12, 2026. Dr. Browne brings over two decades of experience in clinical development and regulatory science, with a particular focus on liver and metabolic diseases. Her expertise includes advancing drug candidates through clinical trials, notably dual GLP-1/glucagon receptor agonists. This appointment is expected to be valuable as MetaVia advances its cardiometabolic pipeline, including DA-1726 and vanoglipel.
Key Highlights
- MetaVia Inc. appointed Sarah Kaplan Browne, M.D. as Chief Medical Officer, effective October 12, 2026.
- Dr. Browne brings over 20 years of experience in clinical development and regulatory science, specializing in liver and metabolic diseases.
- She has extensive experience in advancing drug development programs, including dual GLP-1/glucagon receptor agonists like pemvidutide.
- Dr. Browne previously held leadership roles at Altimmune, Inc. and served at the FDA's Center for Biologics Evaluation and Research (CBER).
Price Impact
More from MTVA